Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Robert James Pearce is active.

Publication


Featured researches published by Robert James Pearce.


European Journal of Pharmacology | 1990

Pharmacological studies in vivo with ICI 169,369, a chemically novel 5-HT2/5-HT1C receptor antagonist

Thomas P. Blackburn; Barry Cox; Craig Willard Thornber; Robert James Pearce

ICI 169,369 (2-(2-dimethylaminoethylthio-3-phenylquinoline hydrochloride) has been tested in vivo for its potency and selectivity as an antagonist at 5-HT2 and 5-HT1C receptors. It caused a 50% inhibition of 5-HTP-induced head twitches in mice and fenfluramine-induced hyperthermia in the rat at approximately 1 mg/kg following parenteral administration. Results showed that ICI 169,369 had good oral bioavailability, since in the fenfluramine test the oral and s.c. ID50 values were similar. ICI 169,369 was a selective antagonist of 5-HT-induced bronchoconstriction in the guinea-pig and 5-HT-induced pressor effects in the anaesthetised dog. In a series of other tests in vivo the compound was shown to be devoid of significant activity at alpha 1- and alpha 2-adrenoceptors, dopamine (D2), muscarinic (M1) and histamine (H1) receptors at 30-100 times its ID50 values used in the 5-HT tests. Thus, ICI 169,369 is a selective, orally active 5-HT2/5-HT1C antagonist that should prove useful in the analysis of the role of 5-HT in physiological and pathological states.


Archive | 1990

Quinoline derivatives, process for their preparation and their use as medicaments

David Anthony Roberts; Simon Thomas Russell; Robert James Pearce


European Journal of Pharmacology | 1988

In vitro studies with ICI 169,369, a chemically novel 5-HT antagonist☆

Thomas P. Blackburn; Craig Willard Thornber; Robert James Pearce; Barry Cox


Journal of Medicinal Chemistry | 1991

Structure activity studies related to 2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted-ethyl]acetamides: a novel series of potent and selective .kappa.-opioid agonists

Jeffrey J. Barlow; Thomas P. Blackburn; Gerard F. Costello; Roger James; David James Le Count; Brian G. Main; Robert James Pearce; Keith Russell; John Shaw


Archive | 1993

1,6-naphthyridinone derivatives having angiotension II antagonist activity

Arnold Harry Ratcliffe; Robert James Pearce; Keith H. Gibson; Robin Wood; Brian B. Masek


Journal of Medicinal Chemistry | 1987

Synthesis and 5-hydroxytryptamine antagonist activity of 2-[[2-(dimethylamino)ethyl]thio]-3-phenylquinoline and its analogues.

Thomas P. Blackburn; Barry Cox; Allen John Guildford; David James Le Count; Derek N. Middlemiss; Robert James Pearce; Craig Willard Thornber


Archive | 1983

Quinoline derivatives which are 5-hydroxytryptamine antagonists

Robert James Pearce; Craig Willard Thornber


Journal of Medicinal Chemistry | 1989

The xanthene-9-spiro-4'-piperidine nucleus as a probe for opiate activity

Ronald Hilson Begg Galt; John Horbury; Zbigniew Stanley Matusiak; Robert James Pearce; John S. Shaw


Archive | 1990

DIAZINE DERIVATIVES AND PHARMACEUTICAL USE

David A. Roberts; Robert James Pearce; Robert H. Bradbury; Richard William Arthur Pitt Street Luke


Archive | 1991

Quinoline and 1,5-Naphthyridine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them

David Anthony Roberts; Robert James Pearce; Robert Hugh Bradbury

Collaboration


Dive into the Robert James Pearce's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Barry Cox

University of Manchester

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David A. Roberts

Imperial Chemical Industries

View shared research outputs
Top Co-Authors

Avatar

Simon Thomas Russell

Imperial Chemical Industries

View shared research outputs
Top Co-Authors

Avatar

Robert H. Bradbury

Imperial Chemical Industries

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge